polyvinyl alcohol embolization microspheres
Phase 1- Indications
- Primary liver cancer
Company intelligence / Profile preview
Shanghai Weimu Medical Technology has developed a high-end interventional medical device platform focused on innovative biomaterials. Its lead product, polyvinyl alcohol embolization microspheres, entered clinical trials for d-TACE in primary liver cancer in early 2022. Another core product, a varicose vein sealing glue, also began clinical evaluation for severe varicose veins. The company is actively expanding its pipeline and R&D capabilities with recent funding rounds. No published pivotal or late-stage results are available as of June 2025.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Weimu Medical Technology.